Effimune announced , the publication in leading scientific journals of three different studies confirming the efficacy of FR104 in new preclinical models, and suggesting that it could be a potent new treatment for rheumatoid arthritis and psoriasis.
The three studies confirm CD28 as an interesting target and FR104 as a potential tool in immune regulation. They demonstrate the effectiveness of the drug candidate in different preclinical models of autoimmune inflammatory diseases:
- Two models of skin inflammation similar to human psoriasis
- A model of joint inflammation associated with rheumatoid arthritis